First IRB approval for APTN-101’s Ph 1 trial in GBM granted, enabling patient recruitment to begin
“Following the successful preclinical development and acceptance of our Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA), we are extremely pleased to receive our first IRB approval for APTN-101’s Phase I clinical trial,” said Michael J. Roberts, Ph.D., Chief Executive Officer of Adaptin Bio. “This represents a major inflection point for our lead program and validates the translation readiness of our targeted bispecific antibody platform. In collaboration with Duke University investigators, the inventors of our BRiTE platform, APTN-101 demonstrated compelling anti-tumor activity and a favorable safety profile in multiple preclinical models. With clinical, manufacturing, and regulatory foundations now in place, we are positioned to advance APTN-101 into the clinic and work toward delivering a meaningful new therapeutic option for patients facing a devastating disease.”
Share:
More News
“FDA clearance of the IND for ORM-1153 is an important milestone for Orum, bringing another first-in-class DAC into the clinic and extending our approach into CD123-expressing hematologic malignancies,” said Olaf Christensen, M.D., Chief Medical Officer of Orum Therapeutics. “By combining cell-selective delivery with targeted protein degradation in a single molecule,
“We are excited to expand our clinical collaboration with Roche to evaluate a second KRAS combination with potential best-in-class MTA-cooperative PRMT5 inhibitor IDE892 for pancreatic cancer patients, where there remains a high unmet medical need. IDEAYA is advancing multiple rational combination strategies for the IDE892 program, including with MAT2A inhibitor
“These encouraging initial safety observations represent an important first step in the clinical evaluation of ZI-MA4-1 and our TCR-NK platform” said Namir Hassan, Chief Executive Officer of Zelluna. “The first patient received all three planned doses, and the independent committee’s recommendation enables us to continue recruitment at the first dose
“Receiving FTD is an important milestone for ERAS-0015 and reflects the urgent need for new therapies for patients with metastatic pancreatic cancer,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Together with the encouraging clinical activity and favorable tolerability observed to date, this FTD helps to position us